$REGN · REGENERON PHARMACEUTICALS, INC. SEC Filings
Position Tracker tracks 13 SEC EDGAR filings for REGENERON PHARMACEUTICALS, INC. ($REGN) from August 12, 2026 through November 4, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 3 Form 8-K current event disclosures, and 8 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$REGN 4 — REGENERON PHARMACEUTICALS, INC.
A director monetized $20.4M in options, a routine but notable insider-sale disclosure.
$REGN 8-K — REGENERON PHARMACEUTICALS, INC.
A 70% non-GAAP EPS surge, record Dupixent sales, and a transformative $8B Sanofi deal in one quarter make this one of the strongest biotech prints of the cycle.
$REGN 10-Q — REGENERON PHARMACEUTICALS, INC.
Regeneron's 36% revenue growth and near-doubling of operating income confirm its two-franchise strategy is working, with Dupixent and EYLEA HD more than compensating for legacy…
$REGN 4 — Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Co-Chief Scientific Officer Andrew J. Murphy filed a Form 4 reporting transactions in the company's common stock on October 13 and 14, 2026. On October…
$REGN 8-K — Regeneron Pharmaceuticals, Inc.
On October 1, 2026, Regeneron Pharmaceuticals, Inc. entered into a Sixth Amendment to its Amended and Restated License and Collaboration Agreement with Sanofi Biotechnology SAS…
$REGN 8-K — Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals filed a current report on Form 8-K disclosing that, effective September 24, 2026, its Compensation Committee and independent board members approved one…
$REGN 4 — Regeneron Pharmaceuticals, Inc.
Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, Inc., filed a Form 4 reporting changes in beneficial ownership on September 3, 2026. The filing discloses sales of R…
$REGN 4 — Regeneron Pharmaceuticals, Inc.
On September 2, 2026, Kathryn Guarini, a director of Regeneron Pharmaceuticals, Inc., exercised non-qualified stock options to acquire 400 shares of common stock at an exercise…
$REGN 4 — Regeneron Pharmaceuticals, Inc.
This Form 4 reports changes in beneficial ownership for Joseph J. LaRosa, Regeneron Pharmaceuticals’ Executive Vice President, General Counsel and Secretary. On August 19, 2026,…
$REGN N-PX — Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. filed a Form N-PX annual report of proxy voting record with the Securities and Exchange Commission for the reporting year ended June 30, 2026. Th…
$REGN 4 — Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals filed a Form 4 reporting transactions by Christopher R. Fenimore, the company’s EVP Finance and CFO. On August 18, 2026, he exercised non-qualified sto…
$REGN 4 — Regeneron Pharmaceuticals, Inc.
A Form 4 filing by Regeneron Pharmaceuticals reports that director Kathryn Guarini executed transactions in the company’s common stock on August 10, 2026. She exercised non-qual…
$REGN 4 — Regeneron Pharmaceuticals, Inc.
A Form 4 filing from Regeneron Pharmaceuticals, Inc. reports stock transactions by director Huda Y. Zoghbi. On August 10, 2026, she exercised a non-qualified stock option to acq…